{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T12:17:05Z","timestamp":1789301825287,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08462"],"award-info":[{"award-number":["21K08462"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08567"],"award-info":[{"award-number":["22K08567"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00600-x","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T16:01:31Z","timestamp":1696435291000},"page":"1623-1636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still\u2019s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"umin000049243","registry":"10.18810\/umin-japan"}],"author":[{"given":"Soichiro","family":"Adachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0025-2617","authenticated-orcid":false,"given":"Kaoru","family":"Takase-Minegishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"issue":"5","key":"600_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","volume":"28","author":"T Mimura","year":"2018","unstructured":"Mimura T, Kondo Y, Ohta A, Iwamoto M, Ota A, Okamoto N, et al. Evidence-based clinical practice guideline for adult Still\u2019s disease. Mod Rheumatol. 2018;28(5):736\u201357.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"600_CR2","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.3390\/jcm10122633","volume":"10","author":"S Mitrovic","year":"2021","unstructured":"Mitrovic S, Fautrel B. Clinical phenotypes of adult-onset Still\u2019s disease: New insights from pathophysiology and literature findings. J Clin Med. 2021;10(12):2633.","journal-title":"J Clin Med"},{"issue":"10","key":"600_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol. 2018;14(10):603\u201318.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"600_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","volume":"30","author":"S Casta\u00f1eda","year":"2016","unstructured":"Casta\u00f1eda S, Blanco R, Gonz\u00e1lez-Gay MA. Adult-onset Still\u2019s disease: Advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30(2):222\u201338.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H. Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167\u201371.","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"600_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","volume":"13","author":"P Ruscitti","year":"2017","unstructured":"Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult-onset Still\u2019s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"600_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","volume":"93","author":"R Giacomelli","year":"2018","unstructured":"Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still\u2019s disease. J Autoimmun. 2018;93:24\u201336.","journal-title":"J Autoimmun."},{"issue":"1","key":"600_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14397595.2021.1899565","volume":"32","author":"T Yamabe","year":"2022","unstructured":"Yamabe T, Ohmura SI, Uehara K, Naniwa T. Macrophage activation syndrome in patients with adult-onset Still\u2019s disease under tocilizumab treatment: a single-center observational study. Mod Rheumatol. 2022;32(1):169\u201376.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"600_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","volume":"58","author":"M Shimizu","year":"2012","unstructured":"Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287\u201394.","journal-title":"Cytokine"},{"issue":"1","key":"600_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21(1):92\u20136.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"600_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","volume":"21","author":"F Vercruysse","year":"2019","unstructured":"Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, et al. Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21(1):53.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"600_CR12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3899\/jrheum.140288","volume":"42","author":"S Yokota","year":"2015","unstructured":"Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712\u201322.","journal-title":"J Rheumatol"},{"issue":"3","key":"600_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon\u00c9-Paut I, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2018;70(3):409\u201319.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"1759720x2110595","DOI":"10.1177\/1759720X211059598","volume":"13","author":"C Kedor","year":"2021","unstructured":"Kedor C, Tomaras S, Baeumer D, Feist E. Update on the therapy of adult-onset Still\u2019s disease with a focus on IL-1-inhibition: a systematic review. Ther Adv Musculoskelet Dis. 2021;13:1759720x211059598.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"600_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","volume":"32","author":"H de Boysson","year":"2013","unstructured":"de Boysson H, F\u00e9vrier J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still\u2019s disease: current clinical evidence. Clin Rheumatol. 2013;32(1):141\u20137.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"600_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/1756-185X.14371","volume":"25","author":"T Naniwa","year":"2022","unstructured":"Naniwa T, Yamabe T, Ohmura SI, Uehara K, Tamechika SY, Maeda S, et al. Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still\u2019s disease receiving interleukin-6 inhibitor treatment. Int J Rheum Dis. 2022;25(9):1003\u201312.","journal-title":"Int J Rheum Dis"},{"issue":"15","key":"600_CR17","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"issue":"3","key":"600_CR18","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19(3):424\u201330.","journal-title":"J Rheumatol"},{"issue":"2","key":"600_CR19","first-page":"119","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull BA. Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions. Am Stat. 1998;52(2):119\u201326.","journal-title":"Am Stat"},{"issue":"9","key":"600_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle\u2013Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"600_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566\u201376.","journal-title":"Arthritis Rheumatol"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3389\/fphar.2019.00918","volume":"10","author":"J Sota","year":"2019","unstructured":"Sota J, Rigante D, Ruscitti P, Insalaco A, Sfriso P, de Vita S, et al. Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult-onset Still disease. Front Pharmacol. 2019;10:918.","journal-title":"Front Pharmacol."},{"key":"600_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: A nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380.","journal-title":"Front Pharmacol"},{"key":"600_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fphar.2019.00296","volume":"10","author":"A Vitale","year":"2019","unstructured":"Vitale A, Cavalli G, Colafrancesco S, Priori R, Valesini G, Argolini LM, et al. Long-term retention rate of anakinra in adult onset Still\u2019s disease and predictive factors for treatment response. Front Pharmacol. 2019;10:296.","journal-title":"Front Pharmacol"},{"key":"600_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","volume":"10","author":"L Rossi-Semerano","year":"2015","unstructured":"Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"600_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerr\u00e9","year":"2008","unstructured":"Lequerr\u00e9 T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"600_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10067-021-05921-2","volume":"41","author":"KT Tang","year":"2022","unstructured":"Tang KT, Hsieh CW, Chen HH, Chen YM, Chang SH, Huang PH, et al. The effectiveness of tocilizumab in treating refractory adult-onset Still\u2019s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clin Rheumatol. 2022;41(2):557\u201366.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"600_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13936","volume":"75","author":"S K\u0131r","year":"2021","unstructured":"K\u0131r S, \u00d6zgen M, Zontul S. Adult-onset still\u2019s disease and treatment results with tocilizumab. Int J Clin Pract. 2021;75(3): e13936.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"600_CR29","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","volume":"7","author":"T Li","year":"2017","unstructured":"Li T, Gu L, Wang X, Guo L, Shi H, Yang C, et al. A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease. Sci Rep. 2017;7(1):13477.","journal-title":"Sci Rep"},{"issue":"2","key":"600_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/14397595.2014.899178","volume":"26","author":"E Bannai","year":"2016","unstructured":"Bannai E, Yamashita H, Kaneko S, Ueda Y, Ozaki T, Tsuchiya H, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still\u2019s disease. Mod Rheumatol. 2016;26(2):297\u2013301.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"600_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3899\/jrheum.130881","volume":"41","author":"O Elkayam","year":"2014","unstructured":"Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult-onset Still\u2019s disease: the Israeli experience. J Rheumatol. 2014;41(2):244\u20137.","journal-title":"J Rheumatol"},{"key":"600_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224123","author":"B Shakoory","year":"2023","unstructured":"Shakoory B, Geerlinks A, Wilejto M, Kernan K, Hines M, Romano M, et al. The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS). Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2023-224123. (Online ahead of print).","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"600_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105524","volume":"90","author":"S Bindoli","year":"2023","unstructured":"Bindoli S, Galozzi P, Doria A, Sfriso P. Intravenous anakinra to curb cytokine storm in adult-onset Still\u2019s disease and in macrophage activation syndrome: a case series. Joint Bone Spine. 2023;90(2): 105524.","journal-title":"Joint Bone Spine"},{"issue":"11","key":"600_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2169\/internalmedicine.53.1488","volume":"53","author":"Y Kiyonaga","year":"2014","unstructured":"Kiyonaga Y, Maeshima K, Imada C, Haranaka M, Ishii K, Shibata H. Steroid-sparing effects of etanercept in a patient with steroid-dependent adult-onset Still\u2019s disease. Intern Med. 2014;53(11):1209\u201313.","journal-title":"Intern Med"},{"issue":"2","key":"600_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64(2):262\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"600_CR36","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1038\/s41467-022-34560-7","volume":"13","author":"J Jia","year":"2022","unstructured":"Jia J, Wang M, Meng J, Ma Y, Wang Y, Miao N, et al. Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still\u2019s disease pathogenesis. Nat Commun. 2022;13(1):6804.","journal-title":"Nat Commun"},{"issue":"5","key":"600_CR37","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/14397595.2017.1422231","volume":"28","author":"Y Kirino","year":"2018","unstructured":"Kirino Y, Kawaguchi Y, Tada Y, Tsukamoto H, Ota T, Iwamoto M, et al. Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still\u2019s disease: a multicenter retrospective study. Mod Rheumatol. 2018;28(5):858\u201364.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"600_CR38","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1093\/rheumatology\/keaa814","volume":"60","author":"H Nagai","year":"2021","unstructured":"Nagai H, Kirino Y, Nakano H, Kunishita Y, Henmi R, Szymanski AM, et al. Elevated serum gasdermin D N-terminal implicates monocyte and macrophage pyroptosis in adult-onset Still\u2019s disease. Rheumatology (Oxf). 2021;60(8):3888\u201395.","journal-title":"Rheumatology (Oxf)"},{"key":"600_CR39","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/jbm7pb","author":"YH Lin","year":"2023","unstructured":"Lin YH, Chang SH, Hsu TC, Chen PK, Lan JL, Chen DY. Elevated monocyte distribution width in patients with active adult-onset Still\u2019s disease: a novel activity indicator. Clin Exp Rheumatol. 2023. https:\/\/doi.org\/10.55563\/clinexprheumatol\/jbm7pb. (Online ahead of print).","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"600_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, D\u00e9cary F, Salusinsky-Sternbach M, et al. Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118\u201336.","journal-title":"Medicine (Baltimore)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00600-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:40:18Z","timestamp":1700152818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00600-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00600-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Soichiro Adachi, Kaoru Takase-Minegishi, Ayaka Maeda, Hideto Nagai, Nobuyuki Horita, Ryusuke Yoshimi, Yohei Kirino, and Hideaki Nakajima have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This meta-analysis is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Concerning the single-center analysis, the protocol and patient\u2019s informed consent documentation were reviewed and approved by the Yokohama City University Ethics Committee (B210200064). The study was conducted according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}